EUDA stock faces vote on proposed dual-class share structure

Published on 11/02/2026 at 00:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EUDA stock shareholders were asked to vote on a dual-class structure at an October 30 meeting. Class B shares would carry 50 votes each.

Governance Vote Puts Control In Focus

EUDA called an extraordinary general meeting to consider a dual-class share structure.
The proposal would give founder-linked holders a substantially stronger voting position if approved.
The board recommended that shareholders support the proposed changes to the company's governing documents.

EUDA, VGG3142E1473, Illustration mit AI erstellt.

EUDA Health Holdings called an extraordinary general meeting for October 30, 2026, to seek approval for a dual-class share structure and amended governing documents. TipRanks reported that the proposal would replace the company's single class of ordinary shares with unlimited Class A shares and 2,000,000 Class B shares.

Proposed Structure Changes Voting Rights

Under the plan, shares held by founder Tan Meng Dong and his controlled vehicle 8i Capital would be reclassified as Class B shares. Each Class B share would carry 50 votes, compared with one vote for a Class A share. The proposal also covers authorized but unissued Class B shares.

TipRanks said the board unanimously recommended that shareholders vote in favor. The company also sought authority to adjourn the meeting if additional proxy solicitation was needed. The filing and meeting notice did not establish the outcome of the vote in the material reviewed here.

Why Governance Matters For Investors

If approved, the structure would give founder-linked holders a much larger share of voting power than their economic ownership. That could strengthen management continuity while reducing the influence of other shareholders on future corporate actions, capital allocation and board matters.

EUDA's Healthcare Platform

EUDA Health Holdings is incorporated in the British Virgin Islands and operates from a Singapore-centered healthcare platform serving markets in Southeast Asia and China. Its website highlights wellness products, bioenergy treatments, stem-cell and immunotherapy programs, and CRISPR-related services. The company is positioning itself around preventive healthcare and longevity rather than a single conventional pharmaceutical product line.